IP Library › Granted Patent US 8,092,798
Granted Patent B2
US 8,092,798 · App. 12/785,975 · Granted Jan 10, 2012

Method of increasing trabecular bone density in a patient in need thereof by an antibody against GDF-8

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,092,798
App. No.
12/785,975
Granted
Jan 10, 2012
Kind
B2
Abstract

The disclosure provides novel antibodies against growth and differentiation factor-8 (GDF-8), including antibody fragments, which inhibit GDF-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism.

Claims (13)

1. A method of increasing trabecular bone density in a patient in need thereof said method comprising administering a therapeutically effective amount of an isolated antibody that specifically binds to amino acids 1-50 of the polypeptide of SEQ ID NO: 15, wherein the antibody reduces a GDF-8 activity, thereby increasing trabecular bone density.

2. The method of claim 1 , wherein the antibody binds to the GDF-8 protein in the region from amino acid 1 to amino acid 25 of the polypeptide of SEQ ID NO: 15.

3. The method of claim 1 , wherein the antibody binds to the GDF-8 protein in the region from amino acid 1 to amino acid 15 of the polypeptide of SEQ ID NO: 15.

4. The method of claim 1 , wherein the antibody binds to the polypeptides of SEQ ID NO: 2.

5. The method of claim 1 , wherein the antibody binds to the polypeptides of SEQ ID NO: 3.

6. The method of claim 1 , wherein the antibody binds to the polypeptides of SEQ ID NO: 5.

7. The method of claim 1 , wherein the antibody binds to the polypeptides of SEQ ID NO: 8.

8. The method of claim 1 , wherein the antibody recognizes the GDF-8 latent complex, GDF-8 in complex with follistatin, or GDF-8 in complex with a follistatin related protein.

9. The method of claim 1 , wherein the antibody is produced by a cell having ATCC Deposit Designation Number PTA-4236.

10. The method of claim 1 , wherein the antibody is chimeric.

11. The method of claim 1 , wherein the antibody is humanized.

12. The method of claim 1 , wherein the antibody is chosen from a single-chain, Fab, F(ab′) 2 , and Fv.

13. The method of claim 1 , wherein the antibody is chosen from IgA, IgD, IgE, IgG, and IgM.

Assignments (1)
CHANGE OF NAME Recorded Jun 16, 2010
From: WYETH
To: WYETH LLC
Reel/Frame 024541/0922 →